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S U M M A R Y

Limited data suggest that tigecycline may be of value in the treatment of Clostridiumdifﬁcile infection. We
reviewed our experience using tigecycline to treat severe c. difﬁcile and compared outcomes to similarly
ill patients who did not receive tigecycline. We found no difference between the groups. Further study is
needed before tigecycline can be recommended for use in severe C. difﬁcile infection.
ß 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/3.0/).
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1. Introduction
The incidence and severity of Clostridium difﬁcile infections
(CDI) have increased over the past decade.1 Despite the availability
of efﬁcacious therapies (vancomycin, metronidazole, ﬁdaxomicin),
severe cases occur and often cause severe morbidity or mortality.
Oral vancomycin has been the mainstay of current treatment for
severe disease, but there are signiﬁcant limitations to its use in
patients with ileus, megacolon, or critical illness.1
Herpers et al. suggested that intravenous (IV) tigecycline, an
agent with in vitro activity against C. difﬁcile, might be useful in
severe CDI based on their experience with four patients.2
Subsequent reports have brought the published cumulative
experience to seven total cases, with success in six.3
Based on these limited data, some of our clinicians have been
using tigecycline in severe cases of C. difﬁcile. We review the
outcomes and compare tigecycline-treated patients to those with
C. difﬁcile of similar severity who did not receive tigecycline.
2. Methods
All patients admitted to our 808-bed medical center during
2011 with a diagnosis of CDI were reviewed. A total of 473
§
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inpatient case records of CDI were examined and stratiﬁed
according to the severity criteria published by Zar et al.4
The diagnosis of severe CDI was established in those with a
compatible clinical syndrome by positive C. difﬁcile toxin B stool
PCR (Cepheid GeneXpert). Severe CDI cases were counted as
tigecycline-treated if they had received IV tigecycline >48 h as part
of their regimen. Observed outcomes included overall survival, rate
of colectomy, recurrence, drug adverse effects, and time to
resolution of diarrhea. Patients who had received IV tigecycline
were further compared to the patient group who had received
standard therapy without tigecycline for severe CDI in a
retrospective unmatched case–control analysis.

3. Results
Eighteen patients received tigecycline >48 h, in addition to
both oral vancomycin and IV metronidazole in 17 patients; the
eighteenth patient received ﬁdaxomicin plus tigecycline. Their
median age was 55 years and median Charlson score was 4; all
fulﬁlled the highest severity criteria, i.e. severe complicated CDI
per the Infectious Diseases Society of America (IDSA) guidelines
(hypotension, shock, ileus, or megacolon).1 Fourteen out of 18
patients survived (78%); four died of multiorgan failure and septic
shock. Two of 14 survivors (14%) required an emergent colectomy.
The median white blood cell count (WBC) was 11.4  109/l at the
initiation of tigecycline. The median duration to resolution of
diarrhea was 4 days. In two out of 18 cases (11%) tigecycline had to
be stopped prematurely due to nausea and vomiting; both
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Table 1
Comparison of serious CDI outcomes by tigecycline usea

Age, years
WBC,  109/l
Serum creatinine, mg/dl
Charlson index
Survival
Colectomy (survivors)
CDI recurrence

Tigecycline
(n = 18)

Non-tigecycline
(n = 26)

55 years
11.4b
1.10b
4
14/18 (78%)
2/14 (14%)
2 (14%)

63 years
13.5
1.15
5
21/26 (80%)
3/21 (14%)
3/21 (14%)

p-Value

0.96
1.0
0.23
1.0
1.0
1.0

CDI, Clostridium difﬁcile infection; WBC, white blood cell count; NS, not signiﬁcant.
a
Results are given as the median or n/N (%).
b
At the time of tigecycline initiation.

survived. Two out of 14 surviving patients (14%) developed
recurrent CDI.
The non-tigecycline severe CDI group of 26 patients had a
median age of 63 years and a median Charlson score of 5. All had
severe CDI per IDSA guidelines and received both vancomycin and
metronidazole therapy. Their median WBC at the time of diagnosis
was 13.5  109/l. Twenty-one of 26 (80%) survived their severe
CDI; ﬁve died. Three of 21 survivors (14%) required a colectomy.
Three out of 21 surviving patients (14%) developed recurrent CDI.
Table 1 summarizes the relevant data; there were no signiﬁcant
differences between the groups.
4. Discussion
Our tigecycline and non-tigecycline treated patients did not
differ with regard to CDI survival, rates of colectomy, or relapse
rates. Two patients treated with tigecycline suffered signiﬁcant
gastrointestinal toxicity, and all had the added expense of this
broad-spectrum agent. The use of tigecycline did not appear to add
beneﬁt, and its use for CDI should be considered unproven. Earlier

small reports of efﬁcacy may have suffered from a positive
reporting bias.2,3
Why tigecycline failed to improve outcomes is unclear. It has
reasonable in vitro activity against C. difﬁcile and is excreted in the
feces.5 Perhaps its broad anaerobic activity negates its activity
against C. difﬁcile.
Our retrospective case–control study is subject to multiple
limitations. The decision as to whether to add tigecycline to
metronidazole and oral vancomycin was strictly at the discretion
of the attending physician. It is possible that more severely ill
patients received tigecycline adjunctive therapy, but baseline data
(WBC, blood pressure, Charlson index, creatinine) do not suggest
this was the case. As in all retrospective case–control designs, a
controlled trial is needed to deﬁnitively determine the role of
tigecycline in C. difﬁcile therapy. Our preliminary data do not
support a role for tigecycline.
Conﬂict of interest: No conﬂicts of interest or funding sources to
declare.
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